SAB Biotherapeutics Company
SAB Biotherapeutics seeks to develop SAB-185 together with CSL Behring. SAB-185 is a high-potency immunotherapy delivering human polyclonal antibodies targeted to SARS-CoV-2, generated from SAB’s proprietary DiversitAb ™ platform.
CSL Behring and SAB Biotherapeutics said April 8 they will partner to develop SAB-185, which they said is expected to be ready for clinical evaluation as early as summer 2020.
CSL Behring and SAB Biotherapeutics said April 8 they will partner to develop SAB-185, which they said is expected to be ready for clinical evaluation as early as summer 2020.
Technology:
COVID
Industry:
Treatments
Headquarters:
United States
Founded Date:
N/A
Employees Number:
N/A
Funding Status:
N/A
Register and Claim Ownership